Date
23 August 2023
New report sets out clear steps for pharma cos to curb AMR risk in antibiotic production
An article in Express Pharma, India's business fortnightly for the pharmaceutical industry, looks at the release of the Foundation's report from its Antimicrobial Resistance (AMR) Programme - 'Methods matter: What steps are companies taking to help curb AMR by manufacturing responsibly?'
Direct links
The article looks at the scope of the report and the companies that provide the examples within it. The three recommendations, for all manufacturers - to employ effective methods to limit AMR risks; to promote compliance with discharge limits across the antibiotic supply chain; and to disclose actions transparently - are detailed.
The article notes that adopting responsible manufacturing practices as a priority now is a necessary move for companies to make their business sustainable and fit for the future, and that investors now view AMR as a systemic risk that needs to be considered within environmental, social and governance (ESG) standard-setting and reporting frameworks.